NexLife does the single most valuable thing a compounded seller can do — it has its preparations independently tested and says what for. It also promises no minimum commitment on one line and asks for thirty days’ notice on another.
No Minimum Commitment, Thirty Days’ Notice
The site states “no minimum commitment required” and, separately, that cancellation requires thirty days’ notice.
Those two statements do not sit together comfortably. A thirty-day notice period is a commitment — a rolling one. Whenever you decide to stop, you are still billed for roughly one more month, so the true minimum is never zero.
This matters more for a GLP-1 than for most subscriptions, because the decision to stop is frequently not a matter of preference. Gastrointestinal side effects are common and a meaningful share of people discontinue in the early months. Someone who stops because they cannot tolerate the medication pays for a further month of a drug they are not taking.
To be fair, thirty days is mild by the standards of this category. We reviewed a provider selling only in four, eight or twelve-month terms with no published cancellation policy at all. A month’s notice is a normal commercial term and probably reflects dispensing lead times rather than a retention trick. The criticism is of the wording, not the term: describing it as “no minimum commitment” overstates what is on offer.
A money-back guarantee is also referenced, with its terms on a separate page rather than set out here. As we found at Curex, guarantees in this market often turn out narrower than the headline. Ask what is refundable once medication has shipped, and how the notice period interacts with it.
The Second Provider to Publish Testing
NexLife states that third-party laboratories test its preparations for potency, sterility, pH and endotoxins, from US-licensed compounding pharmacies within its network.
Those are exactly the right four tests, and they are the same four Curex publishes — the only other provider in our entire review set to do so. Because the FDA does not review compounded preparations for safety, effectiveness or quality, independent assay is the only substantiation available.
Each test answers a real question. Potency confirms the vial contains the labelled dose, which is the central worry with a compounded copy. Sterility and endotoxins are contamination checks — endotoxin is bacterial breakdown product that survives sterilisation and can cause fever and serious reactions when injected. pH affects stability and injection comfort. A page naming those four was written by someone with pharmacy knowledge.
It also states plainly that compounded medications are not approved by the FDA, and notably does not reach for the “FDA-approved pharmacy” framing we have had to correct at several competitors.
Third-Party, or Internal?
One phrase complicates the picture. The testing is described as third-party, but also as part of “internal quality-control procedures”.
Those are reconcilable — a company can commission an outside laboratory as part of its own QC programme, and that is ordinary, legitimate practice. But the two framings answer different questions. Who performs the assay is one thing; who sees the result is another. Testing run internally means the company decides what is done with a failing batch and whether anything is published.
Neither NexLife nor Curex publishes actual certificates of analysis, which is the thing that would close the gap — a batch-level document you can match against the vial you were sent. Ask for the certificate for your batch. A company genuinely running this testing should be able to produce one, and the answer tells you whether the testing is a quality system or a marketing line.
Mid-Market, With a Year-Long Discount
Compounded semaglutide starts at $139 per month and tirzepatide at $169, with a rate as low as $119 a month on a twelve-month plan.
That places NexLife in the middle of the field. It is more expensive than Ozari Health at $86 or TRAVA at $88.65, and far cheaper than the $495 and $695 we found at the top of the market. Paying somewhat more for published testing is a defensible trade — arguably the best reason to pay a premium in this category at all.
The twelve-month rate is worth noting against the earlier point. Committing to a year saves $20 a month, or $240 across the term — a real but modest discount, and one that sits oddly beside “no minimum commitment”. If you take the twelve-month price you have made exactly the commitment the headline says is not required.
Intake is a short online assessment reviewed by a board-certified provider, with eligibility described as turning on clinical factors including BMI and related conditions, though no threshold is published. Shipping is free and stated at one to two days, FSA and HSA cards are accepted, and no states served are listed.
Provider Facts
| Medications offered | Compounded semaglutide and compounded tirzepatide |
|---|---|
| Brand-name or compounded | Compounded, stated plainly as not approved by the FDA; third-party tested for potency, sterility, pH and endotoxins |
| Consultation process | Short online assessment reviewed by a board-certified licensed provider |
| Eligibility | Described as turning on clinical factors including BMI and related conditions; no threshold published. Stated as adults in the US |
| Provider involvement | Board-certified licensed provider reviews health history before prescribing |
| Lab requirements | Not published as a requirement |
| Pharmacy fulfillment | US-licensed compounding pharmacies within NexLife's network; not individually named |
| Shipping frequency | Free and discreet, stated at one to two days once dispatched |
| Support services | Not published in detail |
| Membership fees | None stated |
| Medication fees | Semaglutide from $139 per month and tirzepatide from $169, with a rate as low as $119 per month on a twelve-month plan |
| Cancellation policy | Advertised as no minimum commitment, but requiring thirty days' notice |
| Refund policy | A money-back guarantee is referenced; terms are on a separate page and not set out |
| Insurance | Not billed |
| HSA/FSA | FSA and HSA cards accepted |
| Availability | Not published - stated only as adults in the US, with no state list |
Pros and Cons
Pros
- Publishes third-party testing for potency, sterility, pH and endotoxins
- One of only two providers in our review set to do so
- States plainly that compounded medications are not FDA-approved
- Avoids the “FDA-approved pharmacy” phrasing competitors misuse
- Both molecules named with published starting prices
- Free one-to-two-day shipping; FSA and HSA accepted
- Board-certified provider review before prescribing
Cons
- “No minimum commitment” alongside a thirty-day cancellation notice
- Testing described as third-party but framed as internal quality control
- No certificates of analysis published
- Money-back guarantee referenced without terms
- More expensive than the cheapest published competitors
- No states served, BMI threshold or lab requirement published
Who It May Be Best For
A good fit if independent testing is what you care about most and you are willing to pay somewhat above the cheapest options for it. That is a rational premium — it buys the only substantiation available for a compounded product.
Budget for one extra month. The thirty-day notice means whenever you stop, you pay for roughly a further month. Factor that in rather than treating the plan as cancel-anytime.
Ask for the certificate of analysis for your batch, and for the written money-back guarantee terms. Both are reasonable requests, and the willingness to supply them is informative.
Think twice about the twelve-month rate. Saving $20 a month means committing a year to a medication you may not tolerate past the first few weeks.
Alternatives
Curex publishes the same four tests and serves all 50 states. TRAVA and Ozari Health are cheaper without published testing. Emerge Weight Loss bundles everything into one figure. Our best compounded GLP-1 providers page ranks this segment.
Limitations of This Review
Based on NexLife’s own published materials at nexlife.us, checked on 6 September 2026. Prices are the published starting figures and will rise with dose. We report the testing programme as NexLife describes it and have not reviewed any certificates; our observation about the third-party and internal framings is about how the claim is worded, not an allegation that testing does not occur. The money-back guarantee terms sit on a page we did not reach. Anything marked not published means we could not find it. Nothing here is medical advice.
Frequently Asked Questions
Can I really cancel at any time?
You can cancel, but thirty days’ notice is required — so you are billed for roughly one further month whenever you stop. That is a rolling commitment rather than none, though it is mild compared with the multi-month minimums some competitors impose.
Why does third-party testing matter?
Because the FDA does not review compounded preparations for safety, effectiveness or quality, so independent assay is the only substantiation available. Potency confirms the dose; sterility and endotoxin testing check for contamination in an injectable product.
What does NexLife cost?
Semaglutide from $139 a month and tirzepatide from $169, or as low as $119 a month on a twelve-month plan. These are starting prices and typically rise as the dose escalates.
Which states does it serve?
Not published — only that it serves adults in the US. Telehealth prescribing is licensed state by state, so confirm before completing the assessment.
Verdict
3.3 / 5 — semaglutide from $139, tirzepatide from $169
One of only two compounded sellers we have found publishing independent testing, with honest labelling and accurate regulatory language. Marked down for advertising no minimum commitment while requiring a month’s notice, and for not publishing the certificates that would make the testing checkable.
The point worth carrying beyond this provider: read the cancellation clause against the cancellation promise. “No minimum commitment” and “thirty days’ notice” can appear on the same page, and only the second one is a term of the contract.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from NexLife's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: September 6, 2026